AddLife AB (publ), together with its subsidiaries, provides products, services, and advisory services to private and public sector life science companies in Sweden, Finland, Denmark, Norway, and internationally.
The last earnings update was 9 days ago.
Discounted Cash Flow Calculation for OM:ALIF BTA B using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method. We use
analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
OM:ALIF BTA B DCF 1st Stage: Next 5 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
AddLife's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AddLife has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare AddLife's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare AddLife's earnings growth to the Sweden market average as no estimate data is available.
Unable to compare AddLife's revenue growth to the Sweden market average as no estimate data is available.
Unable to determine if AddLife is high growth as no earnings estimate data is available.
Unable to determine if AddLife is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
AddLife's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
1/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Kristina Willgård, B.Sc. Econ. M.Sc. Econ. has been Chief Executive Officer and President of AddLife AB since 2015. Ms. Willgård serves as Partner and a Board Member at Willgård AB. She served as the Chief Financial Officer of Addtech AB from September 15, 2010 to November 1, 2015. She served as a Finance Director of Ericsson. She served as the President of Addtech Holding AB. She served as Head of Compliance & Control and Chief Financial Officer at Ericsson AB from 2007 to 2010. Ms. Willgård served as Chief Financial Officer of Netwise from 2005 to 2007 and SWE-DISH Satellite Systems AB from 2003 to 2004. She served as Group Controller and Chief Financial Officer of Frontec AB (now Acando AB) from 2001 to 2003. She served as Business controller of Spendrups and Auditor Arthur Andersen. In addition, her previous assignments in finance and accounting from 1989 to 2001. She serves as Chairman of the Board of AddLife Development AB. She has been a Director of Biolin Scientific Holding AB since 2016. She has been a Director of Serneke Group AB since 2015. She is a Member of the Board of Mediplast AB. She served as member of the Board of Addtech Holding AB. She served as Member of the Board of Envilogg AB and Netwise Sverige AB. Ms. Willgård holds a Bachelor of Science in Business and Economics from the University of Lund in 1989.
Kristina's compensation has increased by more than 20% in the past year.
Kristina's remuneration is about average for companies of similar size in Sweden.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the AddLife management team is about average.
President & CEO
Chief Financial Officer
Group Financial Controller
Business Area Manager of Medtech
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the AddLife board of directors is about average.
Board of Directors
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by AddLife insiders in the past 3 months.
AddLife AB (publ), together with its subsidiaries, provides products, services, and advisory services to private and public sector life science companies in Sweden, Finland, Denmark, Norway, and internationally. The company operates through Labtech and Medtech segments. The Labtech segment provides various products and solutions, including analysis instruments, equipment, microscopes, consumables and reagents, as well as application and technical services primarily to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics industries. This segment also offers training programs, seminars, and advisory services. The Medtech segment provides medical device products to various markets, such as surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, home healthcare, surgical equipment, thoracic surgery, and laboratory. AddLife AB (publ) was founded in 1906 and is headquartered in Stockholm, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.